An enzyme immunoassay of ADAMTS13 distiguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations

Thrombosis and Haemostasis

Volumn 91, Issue 4, 2004, Pages 806-811

  Zhou, Wenhua ^a   Tsai, Han Mou ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

ADAMTS13; Enzyme immunoassay; Metalloprotease; Thrombotic thrombocytopenic purpura; von Willebrand factor

Indexed keywords

ARGININE; ASPARTIC ACID; EDETIC ACID; GLUTATHIONE TRANSFERASE; HISTIDINE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOMER; PROTEIN ANTIBODY; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD ANALYSIS; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; GENE MUTATION; GENETIC DISORDER; HETEROZYGOTE; HUMAN; INCUBATION TIME; MICROTITER PLATE ASSAY; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 1842637235     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-11-0675     Document Type: Article

References (13)

1. Bukowski RM. Thrombotic thrombocytopenic purpura. A review. Prog Hemost Thromb 1982; 6: 287-337.
2. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
3. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
5. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
6. Savasan S, Lee SK, Ginsburg D, et al. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 2003; 101: 4449-51.
7. Studt JD, Bohm M, Budde U, et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: A multicenter comparison of different assay methods. J Thromb Haemost 2003; 1: 1882-7.
8. Kokame K, Matsumoto M, Fujimura Y, et al. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2003 (September 25 ePub).
9. Dent JA, Berkowitz SD, Ware J, et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A 1990; 87: 6306-10.
10. Tsai HM. Advances in the Pathogenesis, Diagnosis, and Treatment of Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 2003; 14: 1072-81.
11. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
12. Gerritsen HE, Turecek PL, Schwarz HP, et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-9.
13. Mannucci PM, Canciani MT, Forza I, et al.. Changes in health and disease of the metallo-protease that cleaves von Willebrand factor. Blood 2001; 98: 2730-5.